Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens

被引:51
作者
Ardeshna, KM [1 ]
Kakouros, N
Qian, W
Powell, MG
Saini, N
D'Sa, S
Mackinnon, S
Hoskin, PJ
Goldstone, AH
Linch, DC
机构
[1] Mt Vernon Canc Ctr, Northwood HA6 2RN, Middx, England
[2] UCL Hosp, Dept Haematol, London, England
[3] MRC, Clin Trials Unit, London, England
关键词
salvage chemotherapy; non-Hodgkin's lymphoma; Hodgkin's Lymphoma; autologous stem cell transplant; inadequate partial response;
D O I
10.1111/j.1365-2141.2005.05603.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study aimed to determine the outcome of patients with relapsed or refractory lymphoma who have an inadequate response to first- line salvage therapy (1 degrees ST) and who subsequently receive a second-line salvage regimen (2 degrees ST) with the intention of ultimately proceeding to high-dose therapy. The outcome of 57 patients [ Hodgkin's Lymphoma 17, histologically-aggressive non-Hodgkin's Lymphoma (NHL) 26, histologically-indolent NHL 14] who received more than one modality of conventional- dose salvage therapy was analysed. Sixteen patients had a partial response (PR) to 1 degrees ST, but subsequently received 2 degrees ST because the PR was judged to be inadequate ( iPR) because of persisting disease bulk or marrow infiltration. Of these 16 patients, 10 (63%) continued to respond to 2 degrees ST. Of the 15 patients who had stable disease following 1 degrees ST, 5 (33%) responded to 2 degrees ST. Only one of the 24 (4%) with progressive disease (PD) following 1 degrees ST, responded to 2 degrees ST. 25 of the 57 patients ultimately underwent stem cell transplantation. The 2-year progression-free survival (PFS) and the 3-year overall survival ( OS) for all patients was 24% and 31%, respectively. Long-term survival was highly dependent on response to 1 degrees ST (P = 0.0001); in patients with PD following 1 degrees ST, the PFS and OS at 3 years was only 4%. This analysis indicates that patients with malignant lymphomas, who have PD on 1 degrees ST, are not rescued by subsequent salvage regimens. They should either be treated palliatively or novel approaches should be explored.
引用
收藏
页码:363 / 372
页数:10
相关论文
共 33 条
[1]   High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma [J].
Bierman, PJ ;
Vose, JM ;
Anderson, JR ;
Bishop, MR ;
Kessinger, A ;
Armitage, JO .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :445-450
[2]  
CABANILLAS F, 1982, BLOOD, V60, P693
[3]  
CERVANTES F, 1995, BONE MARROW TRANSPL, V16, P387
[4]  
CHAU ICD, 2003, BLOOD, V102, P1448
[5]   'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma [J].
Chen, CI ;
Roitman, D ;
Tsang, R ;
Stewart, AK ;
Keating, A ;
Crump, M .
BONE MARROW TRANSPLANTATION, 2002, 30 (12) :885-891
[6]   Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].
Cheson, BD ;
Horning, SJ ;
Coiffier, B ;
Shipp, MA ;
Fisher, RI ;
Connors, JM ;
Lister, TA ;
Vose, J ;
Grillo-López, A ;
Hagenbeek, A ;
Cabanillas, F ;
Klippensten, D ;
Hiddemann, W ;
Castellino, R ;
Harris, NL ;
Armitage, JO ;
Carter, W ;
Hoppe, R ;
Canellos, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253
[7]   MINI-BEAM FOLLOWED BY BEAM AND ABMT FOR VERY POOR RISK HODGKINS-DISEASE [J].
CHOPRA, R ;
LINCH, DC ;
MCMILLAN, AK ;
BLAIR, S ;
PATTERSON, KG ;
MOIR, D ;
RICHARDS, JDM ;
CERVI, P ;
KINSEY, S ;
GOLDSTONE, AH .
BRITISH JOURNAL OF HAEMATOLOGY, 1992, 81 (02) :197-202
[8]  
CHOPRA R, 1993, BLOOD, V81, P1137
[9]   MINI-BEAM AS SALVAGE THERAPY FOR RELAPSED OR REFRACTORY HODGKINS-DISEASE BEFORE INTENSIVE THERAPY AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION [J].
COLWILL, R ;
CRUMP, M ;
COUTURE, F ;
DANISH, R ;
STEWART, AK ;
SUTTON, DMC ;
SCOTT, JG ;
SUTCLIFFE, SB ;
BRANDWEIN, JM ;
KEATING, A .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (02) :396-402
[10]   HIGH-DOSE ETOPOSIDE AND MELPHALAN, AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH ADVANCED HODGKINS-DISEASE - IMPORTANCE OF DISEASE STATUS AT TRANSPLANT [J].
CRUMP, M ;
SMITH, AM ;
BRANDWEIN, J ;
COUTURE, F ;
SHERRET, H ;
SUTTON, DMC ;
SCOTT, JG ;
MCCRAE, J ;
MURRAY, C ;
PANTALONY, D ;
SUTCLIFFE, SB ;
KEATING, A .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (04) :704-711